Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab in Rare Cancers with High TMB, MSI-High, or CMMRD (DETERMINE Arm 2)
NCT05770102Phase 3Recruiting
- Sponsor
- Cancer Research UK
- Start
- Oct 2023
- Primary completion
- Oct 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of atezolizumab in rare cancers, solid tumor, lymphoproliferative disorders (LPD), sponsored by Cancer Research UK. Started Oct 2023; status: recruiting.
02
Drugs
atezolizumab
03
Conditions
rare cancerssolid tumorlymphoproliferative disorders (LPD)
Beyond the preview
Go deeper on NCT05770102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05770102.